Jyong Biotech Ltd. (NASDAQ:MENS) Sees Large Decrease in Short Interest

Jyong Biotech Ltd. (NASDAQ:MENS) was the target of a large decrease in short interest during the month of February. As of February 27th, there was short interest totaling 373,692 shares, a decrease of 19.5% from the February 12th total of 464,337 shares. Approximately 0.5% of the company’s shares are short sold. Based on an average daily volume of 422,857 shares, the short-interest ratio is presently 0.9 days. Based on an average daily volume of 422,857 shares, the short-interest ratio is presently 0.9 days. Approximately 0.5% of the company’s shares are short sold.

Jyong Biotech Trading Down 7.9%

Shares of MENS traded down $0.17 during trading hours on Friday, reaching $1.98. 307,226 shares of the company traded hands, compared to its average volume of 329,480. Jyong Biotech has a 12 month low of $1.43 and a 12 month high of $67.00. The company’s fifty day moving average price is $2.55 and its two-hundred day moving average price is $26.74.

Jyong Biotech (NASDAQ:MENS) last released its quarterly earnings results on Friday, January 9th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Institutional Trading of Jyong Biotech

Hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets purchased a new stake in shares of Jyong Biotech in the 3rd quarter worth about $67,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Jyong Biotech during the fourth quarter valued at approximately $49,000. Millennium Management LLC purchased a new stake in shares of Jyong Biotech in the 3rd quarter worth approximately $512,000. Man Group plc bought a new stake in Jyong Biotech in the fourth quarter worth $56,000. Finally, Geode Capital Management LLC grew its stake in shares of Jyong Biotech by 19.6% in the fourth quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock worth $254,000 after acquiring an additional 10,538 shares during the last quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jyong Biotech in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.